Gapping up
News:
- ADVM +10.6% ( Presents 2-Year OPTIC Data)
- OSUR +9.7% (receives $109 mln from DOD for InteliSwab COVID-19 Rapid Test)
- KCAC +7.3% (completes closing of business combination with Wall Box Chargers; will trade on NYSE under ticker "WBX" on Oct 4, 2021)
- PERI +6.4% (acquires Vidazoo; raises FY21 and FY22 guidance)
- XNCR +5.8% (enters global collaboration and license agreement with Janssen (JNJ) to advance plamotamab and xmab cd28 bispecific antibody combinations for the treatment of patients with B-cell malignancies)
- TSLA +2.9% (reports Q3 deliveries)
- ESTE +2.8% (announced that it has entered into definitive agreements to acquire privately held operated assets located in the Midland Basin)
- LYRA +2% (presents new Phase 2 LANTERN 6-Month Follow-Up and LYR-210 pharmacokinetic data)
- ADPT +1.3% (Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease)
- ARQQ +1.1% (files for 117,925,000 share common stock offering by selling shareholders)
- DHT +1% (purchased 1.23 mln of its own shares, or 0.7% of its outstanding shares, during Aug 12-23)
- MCRB +1% (Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021)
Analyst comments:
- DD +2.6% (upgraded to Overweight from Neutral at JP Morgan)
- LUV +1.6% (upgraded to Overweight from Equal Weight at Barclays)
- UNP +1.6% (upgraded to Overweight from Equal Weight at Barclays)
- SJI +1.3% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ROP +1% (upgraded to Strong Buy from Outperform at Raymond James)